22nd Century and KeyGene Achieve Breakthrough in Hemp/Cannabis Plant Transformation
New Capabilities Allow 22nd Century to Accelerate Revenue Streams and Create Higher Value Commercial LinesBUFFALO, N.Y., Feb. 23, 2022 (GLOBE...
Year: 2022
Recce Pharmaceuticals Announces Final Subjects Dosed in Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: Final three subjects in cohort three have been intravenously dosed; RECCE® 327 at 500mg indicating to be safe and...
BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression
Results Distinguish Deep TMS as More Effective in Subjects with Higher Anxiety Symptoms, Long Considered Less Responsive to Alternative TreatmentsBURLINGTON,...
US Patent Office Grants Patent for COVID-19 Risk Test
MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up...
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in Waltham, Massachusetts expected to...
Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors
Interim Results expected mid-2022REHOVOT, Israel and WILMINGTON, Del., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a...
Simply Better Brands Corp. Provides Company Update and 2022 Outlook Driven by Innovation, Channel Expansion and Customer Acquisition
VANCOUVER, British Columbia,, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the “Company” or “Simply Better Brands” or...
InnerScope Hearing Technologies (OTC: INND) Announces New Internal Hearing Aid Sales & Hearing Care Professional Call Center
Staffed by a Highly Experienced Team of Licensed Hearing Professionals and Leading Salespeople from Competitor PlatformsAims to Enhance Customer Experience...
Science 37® to Present at the Cowen 42nd Annual Health Care Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial...
Vystar Adds Vytex into RxAir Spin-off, Sets Spin-Off Record Date, Opens Opportunity for Reverse Merger Into Vystar/Rotmans
Vystar/Rotmans would have singular focus on furniture/bedding industry to be attractive reverse merger opportunityRxAir NewCo would include RxAir®, Vytex® and...
Option Care Health Reports Financial Results for Fourth Quarter and Full Year 2021 and Announces Two Additional Acquisitions
BANNOCKBURN, Ill., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH),...
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional ClassSOUTH SAN FRANCISCO,...
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE)...
Amryt to Report FY and Q4 2021 Results on March 9, 2022
Amryt to Report FY and Q4 2021 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23, 2022,...
Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit
SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
– FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa –– PRECISION-1 tumor agnostic...
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB:...
BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue...
Jushi Holdings Inc. Announces Participation in Upcoming Webinar and Conference
BOCA RATON, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...